Dr. Nasser Hanna, Indiana University Health, lists chemo regiments appropriate for use with radiation in locally advanced NSCLC.
Dr. Nasser Hanna, Indiana University Health, reviews efforts to utilize targeted therapies as consolidation after chemoradiation in locally advanced NSCLC.
Dr. Nasser Hanna, Indiana University Health, considers the use of induction or consolidation chemotherapy for unresectable stage III NSCLC.
Dr. Nasser Hanna, Indiana University Health, discusses the development of chemoradiation as a standard of care for unresectable stage III NSCLC.
Dr. Nasser Hanna, Indiana University Health, describes the factors which determine whether stage III NSCLC is resectable.
Drs. Ben Solomon, Leora Horn, & Jack West consider the range of treatment options for patients with an EGFR mutation and acquired resistance that does not harbor a T790M mutation.
Drs. Ben Solomon, Leora Horn, & Jack West consider the range of treatment options for patients with an EGFR mutation and acquired resistance that does not harbor a T790M mutation.
As we learn more about immunotherapy for lung cancer, combinations with multiple immunotherapy agents are being explored. Medical oncologist Dr. Eddie Garon considers whether combinations are likely to emerge as the leading immunotherapy approach.
As we learn more about immunotherapy for lung cancer, combinations with multiple immunotherapy agents are being explored. Medical oncologist Dr. Eddie Garon considers whether combinations are likely to emerge as the leading immunotherapy approach.
Drs. Leora Horn, Ben Solomon, & Jack West consider whether third generation EGFR TKIs, so active in patients with acquired resistance, might be best used prior to development of acquired resistance.
Hi friends – Hoping you all can provide some insight if you can. I really would love those in the know to interpret what some terms mean with...
Dear Moderators and Doctors I’ve read number of exiting articles published by Spanish group about Silibinin, which is extract of milk thistle. Those...
An FDA press release states that: "On August 16, 2018, the Food and Drug Administration granted accelerated approval to nivolumab (Opdivo, Bristol...
Dear Moderators and Doctors I’ve read number of exiting articles published by Spanish group about Silibinin, which is extract of milk thistle. Those...
I was reading the article by Dr West, How long should we continue immune checkpoint inhibitor therapy in patients who respond? This was written in...
Drs. Nasser Hanna and Melissa Johnson discuss developments in Immunotherapy since ASCO 2013.
[powerpress]
Drs. Nasser Hanna and Melissa Johnson discuss new trial evidence for the use of adjuvant Erlotinib for early-stage lung cancer.
[powerpress]
Dr. Nasser Hanna outlines the possible benefits of consolidation chest radiation for small cell lung cancer patients who respond well to chemotherapy.
[powerpress]
The doctors discuss the circumstances under which small cell lung cancer patients should receive prophylactic cranial irradiation.
[powerpress]
Dr. Nasser Hanna discusses the SQUIRE trial of the EGFR antibody Necitumumab in patients with squamous lung cancer. Though it achieved a statistical increase in OS, he does not consider it clinically relevant.
[powerpress]
The REVEL trial studied 1,200 non-small cell lung cancer patients to see if the drug Cyramza (ramucirumab) improved overall surival. The doctors had mixed feelings about the results.
[powerpress]
The doctors discuss the new FDA-approved drug for ALK positive lung cancer patients, Zykadia (ceritinib), including the dosage level, potential side effects and the ability of Zykadia to impact brain metastases.
[powerpress]
We have seen over the past decade that patient self-education and participation in their own care have been steadily increasing with availability of the Internet. It has enabled patients and caregivers to look online for information as well as to connect with other people in the patient community who can provide both knowledge of available treatment options and suppor
"Dead negative," is how Dr. Nasser Hanna describes results of a phase 3 study that examined how patients with high MET expression did on the drug MetMab (onartuzumab).
[powerpress]
One of the ongoing questions in managing EGFR mutation-positive advanced NSCLC has been whether it should be routine to do repeat biopsies to look for new findings after a patient has developed acquired resistance to an EGFR tyrosine kinase inhibitor (TKI). Here are a few posts in which the topic has been covered:
Welcome to the new CancerGRACE.org! Explore our fresh look and improved features—take a quick tour to see what’s new.